We just received data on a new analyst forecast for $INCY. Derek Archila from Wells Fargo set a price target of 107.0 for INCY.
To track analyst ratings and price targets for $INCY, check out Quiver Quantitative's $INCY forecast page.
Should you buy $INCY?
Some analysts are better than others. To view the past performance of Wells Fargo, check out Quiver’s Analyst Ratings dashboard. You can also see Quiver’s Analyst Buys Strategy, which uses a proprietary method to track the companies being recommended by the top Wall Street analysts.
$INCY Price Targets
Multiple analysts have issued price targets for $INCY recently. We have seen 17 analysts offer price targets for $INCY in the last 6 months, with a median target of $102.0.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $107.0 on 01/20/2026
- Marc Frahm from TD Cowen set a target price of $128.0 on 01/13/2026
- Vikram Purohit from Morgan Stanley set a target price of $94.0 on 01/06/2026
- Salim Syed from Mizuho set a target price of $121.0 on 12/08/2025
- Etzer Darout from Barclays set a target price of $115.0 on 11/24/2025
- Allison Bratzel from Piper Sandler set a target price of $102.0 on 11/04/2025
- Michael Schmidt from Guggenheim set a target price of $125.0 on 11/03/2025
$INCY Insider Trading Activity
$INCY insiders have traded $INCY stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months:
- HERVE HOPPENOT sold 187,500 shares for an estimated $19,773,750
- MICHAEL JAMES MORRISSEY (EVP, Head of Tech. Operations) has made 0 purchases and 3 sales selling 58,331 shares for an estimated $5,675,001.
- STEVEN H STEIN (EVP & Chief Medical Officer) has made 0 purchases and 4 sales selling 43,531 shares for an estimated $4,449,228.
- MOHAMED KHAIRIE ISSA (EVP, Head of US Oncology) sold 10,856 shares for an estimated $1,184,063
- SHEILA A. DENTON (EVP & General Counsel) has made 0 purchases and 9 sales selling 7,004 shares for an estimated $608,468.
- PATRICK A MAYES (EVP & Chief Scientific Officer) has made 0 purchases and 2 sales selling 5,808 shares for an estimated $554,965.
- THOMAS TRAY (Principal Accounting Officer) has made 0 purchases and 2 sales selling 3,374 shares for an estimated $336,350.
- LEE HEESON (EVP, Head of Incyte Intl) sold 3,074 shares for an estimated $289,017
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$INCY Revenue
$INCY had revenues of $1.4B in Q3 2025. This is an increase of 20.05% from the same period in the prior year.
You can track INCY financials on Quiver Quantitative's INCY stock page.
$INCY Hedge Fund Activity
We have seen 390 institutional investors add shares of $INCY stock to their portfolio, and 302 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOS ANGELES CAPITAL MANAGEMENT LLC added 1,447,728 shares (+461.9%) to their portfolio in Q3 2025, for an estimated $122,781,811
- PACER ADVISORS, INC. added 1,233,399 shares (+8091.6%) to their portfolio in Q3 2025, for an estimated $104,604,569
- MARSHALL WACE, LLP removed 1,195,191 shares (-98.7%) from their portfolio in Q3 2025, for an estimated $101,364,148
- CAISSE DE DEPOT ET PLACEMENT DU QUEBEC added 1,087,091 shares (+264.5%) to their portfolio in Q3 2025, for an estimated $92,196,187
- ROYAL BANK OF CANADA added 1,058,178 shares (+247.5%) to their portfolio in Q3 2025, for an estimated $89,744,076
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,036,518 shares (+52.6%) to their portfolio in Q3 2025, for an estimated $87,907,091
- DODGE & COX removed 662,765 shares (-4.5%) from their portfolio in Q3 2025, for an estimated $56,209,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
